



Abbott India Ltd
Godrej BKC, Plot C-68, G. Block,
16th Floor, Bandra Kurla Complex,
Near MCA Club, Bandra (E),
Mumbai - 400 051. INDIA

Registered Office:
3-4, Corporate Park,
Sion Trombay Road,
Mumbai -400 071. India

Tel : (91-22) 3816 1000
Fax : (91-22) 3816 2401
E-mail : webmaster@abbott.co.in
Site : www.abbott.co.in
CIN : L24239MH1944PLC007330

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017

(Rs. in Lakhs except earnings per share)

Particulars	Quarter ended			Nine Months ended		Year ended
	December 31, 2017	September 30, 2017	December 31, 2016	December 31, 2017	December 31, 2016	March 31, 2017
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income from Operations						
(a) Revenue from operations	881.49	930.98	755.72	2527.20	2223.27	2938.69
(b) Other income	19.00	15.06	13.90	49.97	42.19	57.64
Total Income	900.49	946.04	769.62	2577.17	2265.46	2996.33
2 Expenses						
(a) Cost of materials consumed	82.66	64.03	76.39	225.37	244.21	315.94
(b) Purchases of stock-in-trade	571.82	367.10	428.95	1368.79	1227.59	1497.56
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(141.14)	90.42	(64.70)	(121.29)	(182.06)	(101.44)
(d) Excise duty on sales	-	-	9.18	8.62	26.37	36.13
(e) Employee benefits expense	91.13	98.28	87.85	286.04	260.51	345.27
(f) Finance cost	51	59	1	1.61	4	2.04
(g) Depreciation and amortisation expense	4.22	4.04	4.35	12.23	12.59	16.43
(h) Other expenses	113.68	109.81	94.99	333.35	312.20	447.91
Total Expenses	722.88	734.27	637.02	2114.72	1901.45	2559.84
3 Profit before tax (1-2)	177.61	211.77	132.60	462.45	364.01	436.49
4 Tax expense						
(a) Current tax expense	64.42	75.12	47.15	165.15	130.11	156.88
(b) Tax adjustment for earlier years	(2.55)	-	-	(2.55)	-	4.96
(c) Deferred tax (Credit)	35	(87)	(11)	(1.31)	(69)	(2.00)
Total Tax expenses	62.22	74.25	47.04	161.29	129.42	159.84
5 Net Profit for the period (3-4)	115.39	137.52	85.56	301.16	234.59	276.65
6 Other Comprehensive Income						
- Items that will not be reclassified to Profit or Loss	(72)	(72)	-	(2.16)	-	(2.87)
- Income tax relating to above items	25	25	-	75	-	99
Total Other Comprehensive Income, net of tax	(47)	(47)	-	(1.41)	-	(1.88)
7 Total Comprehensive Income for the period (5+6)	114.92	137.05	85.56	299.75	234.59	274.77
8 Paid-up Equity Share Capital (Face Value Rs.10 per Equity Share)	21.25	21.25	21.25	21.25	21.25	21.25
9 Earnings per equity share - Basic/Diluted (of Rs.10/- each) (not annualised)	54.30	64.72	40.26	141.72	110.40	130.19


SIGNED FOR IDENTIFICATION
BY
S R B C & CO LLP
MUMBAI

See Ar

NOTES :


- 1 The above financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on February 14, 2018. The statutory auditors have carried out a limited review of the results for the quarter and nine months ended December 31, 2017.
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated July 5, 2016.
- 3 The Government of India has implemented Goods and Services Tax ('GST') with effect from July 1, 2017 which replaced excise duty and various other indirect taxes. As per Ind AS 18, the revenue for the quarter ended December 31, 2017 and September 30, 2017 is reported net of GST. However, revenue for the nine months ended December 31, 2017 includes excise duty upto June 30, 2017. Accordingly, the revenue for the quarter and nine months ended December 31, 2017 are not strictly comparable to the preceding periods.
- 4 The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.
- 5 Figures for the previous periods have been regrouped/reclassified wherever considered necessary.

SIGNED FOR IDENTIFICATION
BY 
S R B C & CO LLP
MUMBAI

Place : 
Date : February 14, 2018



For and on behalf of the Board of Directors of
Abbott India Limited



Ambati Venu
Managing Director
DIN : 07614849